Affymax Receives $10 Million Milestone Payment from Takeda
August 10, 2011
Affymax, Inc. today announced that it has received a $10 million development milestone payment from Takeda Pharmaceutical Company as part of the companies’ exclusive global agreement to develop and commercialize peginesatide (formerly known as Hematide™), Affymax’s investigational drug for the treatment of anemia in chronic renal failure patients, according to a press release. The payments were triggered by the acceptance and filing of the New Drug Application for peginesatide by the FDA. If approved, peginesatide will be the first once-monthly erythropoiesis stimulating agent (ESA) available for the treatment of anemia associated with CKD patients on dialysis in the United States.